Navigation Links
Cell Genesys Reports Association Between Immune Response and Patient Survival in Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
Date:2/15/2008

tere(R) (docetaxel) chemotherapy plus prednisone in HRPC patients with metastatic disease who are asymptomatic with respect to cancer-related pain. The primary endpoint of the trial is an improvement in survival. An interim analysis of the trial was recently conducted by an independent data monitoring committee in the timeframe originally estimated and resulted in the recommendation to continue the trial. The company expects to have enough events to trigger the final analysis of VITAL-1 in the second half of 2009. VITAL-2, which the company expects to fully enroll with approximately 600 patients in the first half of 2009, is designed to evaluate the safety and efficacy of GVAX immunotherapy for prostate cancer used in combination with Taxotere chemotherapy compared to the use of Taxotere chemotherapy and prednisone in HRPC patients with metastatic disease who are symptomatic with cancer-related pain. The primary endpoint of the trial is also an improvement in survival. The company expects to have enough events to trigger an interim analysis of VITAL-2 in the first half of 2009.

About GVAX Cancer Immunotherapies

GVAX cancer immunotherapies are non patient-specific investigational products comprised of whole tumor cells that have been modified to secrete GM- CSF (granulocyte-macrophagecolony-stimulating factor), an immune stimulatory cytokine, and then irradiated for safety. GVAX is administered via intradermal injections on an outpatient basis. To date, over 600 patients have been treated with GVAX cancer immunotherapies in Phase 1 and Phase 2 clinical trials for multiple indications, including prostate cancer, pancreatic cancer, and leukemia. The company is currently manufacturing GVAX immunotherapy for prostate cancer in its bioreactor-based manufacturing plant in Hayward, California, a facility that is also capable of manufacturing the product for commercialization.

About Cell Genesys

Cell Genesys is focused on the development and comme
'/>"/>

SOURCE Cell Genesys, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
2. Pharmasset Reports First Fiscal Quarter 2008 Financial Results
3. CEL-SCI Corporation Reports First Quarter Financial Results
4. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
5. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
6. Cystic Fibrosis Foundation Reports Upward Trend for Key Health Outcomes
7. Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)
8. Study Reports Successful Cloning of Human Embryo Using Adult DNA
9. Schering-Plough Reports Top-Line Results of the IDEAL Study
10. Second Thoughts about Fluoride, Reports Scientific American
11. SuperGen Reports Initiation of Multi-arm Phase 1b Trial of Novel Tyrosine Kinase Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ... forma net operating loss (NOL) guidance and its cash ...  Isis, significantly improved financial results were due in large ... the Company received from its partners.  Isis, pro forma ... 60% improvement over its 2013 NOL of $40.2 million. ...
(Date:2/27/2015)...  Boston Scientific Corporation (NYSE: BSX ) ... Healthcare Conference on March 10 in Miami ... executive vice president and chief financial officer, and ... in a 25-minute question and answer session regarding the ... ET. Following a 5-minute break, a question and answer ...
(Date:2/27/2015)... KING OF PRUSSIA, Pa. , Feb. 27, 2015 ... part of its ongoing commitment to the global bleeding ... it is donating 2 million international units (IUs) of ... WFH is an international not-for- profit organization which has ... and other inherited bleeding disorders. The donation supports the ...
Breaking Medicine Technology:Isis Reports Financial Results and Highlights for 2014 2Isis Reports Financial Results and Highlights for 2014 3Isis Reports Financial Results and Highlights for 2014 4Isis Reports Financial Results and Highlights for 2014 5Isis Reports Financial Results and Highlights for 2014 6Isis Reports Financial Results and Highlights for 2014 7Isis Reports Financial Results and Highlights for 2014 8Isis Reports Financial Results and Highlights for 2014 9Isis Reports Financial Results and Highlights for 2014 10Isis Reports Financial Results and Highlights for 2014 11Isis Reports Financial Results and Highlights for 2014 12Isis Reports Financial Results and Highlights for 2014 13Isis Reports Financial Results and Highlights for 2014 14Isis Reports Financial Results and Highlights for 2014 15Isis Reports Financial Results and Highlights for 2014 16Isis Reports Financial Results and Highlights for 2014 17Boston Scientific to Participate in the Barclays 2015 Annual Healthcare Conference 2CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of Hemophilia 2CSL Behring Continues Treatment Access Leadership by Donating Bleeding Disorder Protein Therapies IUs to World Federation of Hemophilia 3
... 15, 2011 The FDA today issued draft ... quality clinical studies in support of premarket approval ... http://photos.prnewswire.com/prnh/20090824/FDALOGO ) Manufacturers submit ... These applications undergo the most stringent type of ...
... Astellas US, LLC ("Astellas") recently named Percival Barretto-Ko ... Affairs, a new position added to the company,s ... Yoshida, Barretto-Ko will be responsible for corporate planning, ... state government affairs. "This realignment brings ...
Cached Medicine Technology:FDA Seeks Comment on Proposed Guidelines for High-Quality Clinical Studies 2Astellas Expands Leadership Team With Senior Vice President of Corporate Strategy and Government Affairs 2
(Date:2/28/2015)... On Thursday, February 26th, Forbes published an article ... To Steal Your Data , which stresses the ease with ... DIY phishing kit, or any kind of malware kit for ... point about how everyone’s cyber security is intertwined when it ... legitimate content management systems or blogs in order to install ...
(Date:2/28/2015)... 28, 2015 Javon Bea Mercy ... Harvard Hospital as stroke capable by the State of ... ambulance to Mercy Harvard Hospital. , The hospital was ... their ability to treat stroke according to national standards ... transporting stroke patients to bypass hospitals not designated as ...
(Date:2/28/2015)... February 28, 2015 The World Scout ... learning materials to potential EMTs and firefighters, recently announced ... as a way to raise charitable donations for age-related ... Medellin, Columbia, will be held on March 29, 2015; ... will begin at 3:30 p.m. , To participate ...
(Date:2/27/2015)... Wireless Analytics, an award-winning ... of the founders of the wireless expense ... within their CLEAN Platform™ (Communications Lifecycle Expense Analytics) ... newly developed Bell Mobility Data Loader enables unprecedented ... carrier’s business customers. , Wireless Analytics cites customer ...
(Date:2/27/2015)... 2015 Those who self-injure, ... misunderstood, misdiagnosed and therefore aren’t receiving effective ... Jacksonville-based addiction treatment center Lakeview Health ... acclaimed Lakeview Professional Lecture Series to counselors, ... this complicated condition. , “Self-injurious ...
Breaking Medicine News(10 mins):Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 2Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 3Health News:DIY Phishing and Malware Kits Make it Easy to Compromise Businesses in More Ways than One 4Health News:Mercy Harvard Hospital Recognized as Leader in Stroke Care - Javon Bea 2Health News:Bitcoin Run Is The World Scout League Commission’s Newest Project for Charity 2Health News:Bell Mobility Gains Traction With Enterprises; Is Added to Wireless Analytics’ CLEAN Platform™ 2Health News:Bell Mobility Gains Traction With Enterprises; Is Added to Wireless Analytics’ CLEAN Platform™ 3Health News:Lakeview Health to Host Important Workshop Tackling the Rising Issue of ‘Cutters’ on March 27 2
... SILVER SPRING, Md., Aug. 3 Four simple ... of ongoing couples therapy can greatly increase chances for reconciliation ... largest clinical trial with couples to date, it shows that ... technique were 46.2 percent less than that of couples who ...
... , HATBORO, Pa., August 3 ... IFLG ), a leading technology provider of enterprise mobility solutions ... of a new mobility offering for healthcare providers, the InfoLogix ... enables medical professionals to access critical patient information at the ...
... research , MONDAY, Aug. 3 (HealthDay News) -- Common variants ... an increased risk of pancreatic cancer, according to U.S. researchers. ... cancer patients and more than 4,500 people without the disease. ... gene that produce the blood types A, B or AB ...
... , , BERKELEY HEIGHTS, N.J., ... ADAT ), a worldwide provider of secure ... announced that Medical Services of America, Inc., a ... equipment, headquartered in Lexington South Carolina, will implement ...
... , , , RIDGEFIELD, ... International Association for the Study of Lung Cancer,s 13th World ... of a Phase III clinical study of BIBW 2992 as ... epidermal growth factor receptor (EGFR) mutations. BIBW 2992 is ...
... , MOUNTAIN VIEW, Calif., Aug. 3 ... for the second quarter ended June 30, 2009. , , ... $5.0 million, compared to $16.5 million during the same period in 2008. ... million, compared to $30.8 million for the first six months of 2008. ...
Cached Medicine News:Health News:Therapy Technique Cuts Divorce/Separation Rate By Nearly 50 Percent 2Health News:New InfoLogix M24 Mobile Clinical Assistant Will Enable Hospitals to Access Electronic Medical Records (EMR) Directly at the Point of Care 2Health News:New InfoLogix M24 Mobile Clinical Assistant Will Enable Hospitals to Access Electronic Medical Records (EMR) Directly at the Point of Care 3Health News:Blood Type May Boost Pancreatic Cancer Risk 2Health News:Medical Services of America Selects Authentidate's Inscrybe Healthcare to Standardize Healthcare Order Process Management 2Health News:Medical Services of America Selects Authentidate's Inscrybe Healthcare to Standardize Healthcare Order Process Management 3Health News:Medical Services of America Selects Authentidate's Inscrybe Healthcare to Standardize Healthcare Order Process Management 4Health News:Boehringer Ingelheim to Commence Phase III Study Investigating the Role of BIBW 2992 as First-Line Treatment for Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR Mutations 2Health News:Boehringer Ingelheim to Commence Phase III Study Investigating the Role of BIBW 2992 as First-Line Treatment for Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR Mutations 3Health News:Boehringer Ingelheim to Commence Phase III Study Investigating the Role of BIBW 2992 as First-Line Treatment for Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR Mutations 4Health News:Boehringer Ingelheim to Commence Phase III Study Investigating the Role of BIBW 2992 as First-Line Treatment for Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR Mutations 5Health News:Boehringer Ingelheim to Commence Phase III Study Investigating the Role of BIBW 2992 as First-Line Treatment for Non-Small Cell Lung Cancer (NSCLC) Patients with EGFR Mutations 6Health News:MAP Pharmaceuticals Reports Second Quarter of 2009 Financial Results 2Health News:MAP Pharmaceuticals Reports Second Quarter of 2009 Financial Results 3Health News:MAP Pharmaceuticals Reports Second Quarter of 2009 Financial Results 4Health News:MAP Pharmaceuticals Reports Second Quarter of 2009 Financial Results 5Health News:MAP Pharmaceuticals Reports Second Quarter of 2009 Financial Results 6Health News:MAP Pharmaceuticals Reports Second Quarter of 2009 Financial Results 7
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: